Extended report
Soluble urokinase plasminogen activator receptor in plasma of
patients with inflammatory rheumatic disorders: increased
concentrations in rheumatoid arthritis
Ole Slota, Nils Brünnerb, Henning Lochta, Peter Oxholma, Ross W Stephensb
a Department of
Rheumatology, Copenhagen County Hospital Gentofte, DK-2900 Hellerup,
Denmark, b Finsen Laboratory, Copenhagen University
Hospital, Copenhagen, Denmark
Correspondence to: Dr O Slot.
Accepted for publication 12 April 1999
OBJECTIVE
Urokinase
type plasminogen activator (uPA) catalyses the formation of the
proteolytic enzyme plasmin, which is involved in matrix degradation in
the processes of tissue remodelling. Because of a surface bound uPA
receptor (uPAR), expressed by some cell types (for example,
macrophages, malignant cells and inflammatory activated synoviocytes),
the action of uPA can be localised and intensified. uPAR seems to have
a role in the mechanisms leading to invasive growth of malignant tissue
and the rheumatoid pannus. uPAR may become cleaved at its cell surface
anchor, thus forming a free soluble receptor (suPAR). suPAR is
detectable in low but constant values in plasma of healthy people,
while increased concentrations are found in patients with disseminated
malignant disease, so that suPAR may be an indicator of invasive growth
and tissue remodelling. suPAR concentrations in plasma have not
previously been measured in rheumatic patients. A controlled cross
sectional measurement was performed of suPAR in plasma of patients with
various inflammatory rheumatic disorders with special reference to
rheumatoid arthritis (RA).
METHODSsuPAR in
plasma was measured by ELISA technique in patients with RA (n=51),
reactive arthritis (ReA) (n=23), primary Sjögren's syndrome (PSS)
(n=42) and sex and age matched healthy controls (n=53).
RESULTSIn the control
group suPAR (median) was 0.91 (range 0.56-1.94) µg/l. Median suPAR
value in RA was 1.47 (range 0.65-6.62) µg/l; in ReA 0.68 µg/l
(range 0.52-1.48) and in PSS 1.12 µg/l (range 0.76-1.92); p versus
controls <0.001 in all patient groups. suPAR values in RA were also
significantly increased compared with ReA (p<0.001) and PSS (p=0.004)
groups. suPAR in RA was positively correlated to C reactive protein
(CRP) (p<0.01) and erythrocyte sedimentation rate (p<0.05) and number
of swollen joints (p<0.05). The ReA group had the highest CRP values
of all groups, but at the same time the lowest suPAR concentrations in plasma.
CONCLUSIONSIncreased
suPAR concentrations were found in plasma in RA, and to a smaller
extent also in PSS, but not in ReA. In RA suPAR is related to disease
activity. suPAR seems though not merely to be an acute phase reactant
like CRP. Increased suPAR values might reflect erosive activity in RA.
© 1999 by Annals of the Rheumatic Diseases
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
-
Park, Y.-J., Liu, G., Tsuruta, Y., Lorne, E., Abraham, E.
(2009). Participation of the urokinase receptor in neutrophil efferocytosis. Blood
114: 860-870
[Abstract] [Full Text] -
Shushakova, N., Eden, G., Dangers, M., Zwirner, J., Menne, J., Gueler, F., Luft, F. C., Haller, H., Dumler, I.
(2005). The Urokinase/Urokinase Receptor System Mediates the IgG Immune Complex-Induced Inflammation in Lung. J. Immunol.
175: 4060-4068
[Abstract] [Full Text] -
Beaufort, N., Leduc, D., Rousselle, J.-C., Magdolen, V., Luther, T., Namane, A., Chignard, M., Pidard, D.
(2004). Proteolytic Regulation of the Urokinase Receptor/CD87 on Monocytic Cells by Neutrophil Elastase and Cathepsin G. J. Immunol.
172: 540-549
[Abstract] [Full Text] -
Coleman, J. L., Benach, J. L.
(2003). The Urokinase Receptor Can Be Induced by Borrelia burgdorferi through Receptors of the Innate Immune System. Infect. Immun.
71: 5556-5564
[Abstract] [Full Text] -
Coleman, J. L., Gebbia, J. A., Benach, J. L.
(2001). Borrelia burgdorferi and Other Bacterial Products Induce Expression and Release of the Urokinase Receptor (CD87). J. Immunol.
166: 473-480
[Abstract] [Full Text] -
Mustjoki, S., Sidenius, N., Sier, C. F. M., Blasi, F., Elonen, E., Alitalo, R., Vaheri, A.
(2000). Soluble Urokinase Receptor Levels Correlate with Number of Circulating Tumor Cells in Acute Myeloid Leukemia and Decrease Rapidly during Chemotherapy. Cancer Res.
60: 7126-7132
[Abstract] [Full Text] -
SLOT, O., BRÜNNER, N., STEPHENS, R. W
(2000). Marker of erosive progression in RA. Ann Rheum Dis
59: 654c-654
[Full Text] -
Tarui, T., Mazar, A. P., Cines, D. B., Takada, Y.
(2001). Urokinase-type Plasminogen Activator Receptor (CD87) Is a Ligand for Integrins and Mediates Cell-Cell Interaction. J. Biol. Chem.
276: 3983-3990
[Abstract] [Full Text]
- Full Text
- Full Text (PDF)
- Submit a response
- Alert me when this article is cited
- Alert me when eLetters are posted
- Alert me if a correction is posted
- Citation Map
Services
- Email this link to a friend
- Similar articles in this journal
- Similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Topic Collections
-
Connective tissue disease
-
Musculoskeletal syndromes
-
Rheumatoid arthritis
-
Immunology (including allergy)
- Degenerative joint disease
Bookmark with
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
